Compare Sun Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs GLENMARK PHARMA - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA GLENMARK PHARMA SUN PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 27.4 15.7 174.3% View Chart
P/BV x 2.8 2.2 127.3% View Chart
Dividend Yield % 0.6 0.5 124.7%  

Financials

 SUN PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
GLENMARK PHARMA
Mar-19
SUN PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs679712 95.4%   
Low Rs375484 77.6%   
Sales per share (Unadj.) Rs121.1349.6 34.6%  
Earnings per share (Unadj.) Rs13.432.8 40.8%  
Cash flow per share (Unadj.) Rs20.744.3 46.7%  
Dividends per share (Unadj.) Rs2.752.00 137.5%  
Dividend yield (eoy) %0.50.3 155.9%  
Book value per share (Unadj.) Rs172.6198.6 86.9%  
Shares outstanding (eoy) m2,399.26282.17 850.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.41.7 254.6%   
Avg P/E ratio x39.418.2 216.2%  
P/CF ratio (eoy) x25.513.5 189.0%  
Price / Book Value ratio x3.13.0 101.5%  
Dividend payout %20.66.1 337.0%   
Avg Mkt Cap Rs m1,264,650168,625 750.0%   
No. of employees `00017.512.0 145.4%   
Total wages/salary Rs m59,67120,561 290.2%   
Avg. sales/employee Rs Th16,608.18,196.0 202.6%   
Avg. wages/employee Rs Th3,409.61,708.1 199.6%   
Avg. net profit/employee Rs Th1,833.8768.5 238.6%   
INCOME DATA
Net Sales Rs m290,65998,655 294.6%  
Other income Rs m10,2552,081 492.7%   
Total revenues Rs m300,914100,736 298.7%   
Gross profit Rs m63,07615,858 397.8%  
Depreciation Rs m17,5333,259 538.0%   
Interest Rs m5,5533,346 165.9%   
Profit before tax Rs m50,24611,335 443.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1441,672 -726.4%   
Tax Rs m6,0093,756 160.0%   
Profit after tax Rs m32,0939,250 347.0%  
Gross profit margin %21.716.1 135.0%  
Effective tax rate %12.033.1 36.1%   
Net profit margin %11.09.4 117.8%  
BALANCE SHEET DATA
Current assets Rs m310,69266,968 463.9%   
Current liabilities Rs m173,39640,211 431.2%   
Net working cap to sales %47.227.1 174.2%  
Current ratio x1.81.7 107.6%  
Inventory Days Days9983 118.9%  
Debtors Days Days11281 137.4%  
Net fixed assets Rs m232,47733,322 697.7%   
Share capital Rs m2,399282 850.2%   
"Free" reserves Rs m411,69155,770 738.2%   
Net worth Rs m414,09156,052 738.8%   
Long term debt Rs m15,22635,738 42.6%   
Total assets Rs m646,938132,888 486.8%  
Interest coverage x10.04.4 229.0%   
Debt to equity ratio x00.6 5.8%  
Sales to assets ratio x0.40.7 60.5%   
Return on assets %5.89.5 61.4%  
Return on equity %7.816.5 47.0%  
Return on capital %10.217.8 57.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,02562,998 104.8%   
Fx outflow Rs m38,61022,859 168.9%   
Net fx Rs m27,41540,140 68.3%   
CASH FLOW
From Operations Rs m21,96513,242 165.9%  
From Investments Rs m-6,813-6,990 97.5%  
From Financial Activity Rs m-27,305-7,387 369.6%  
Net Cashflow Rs m-8,442-2,971 284.1%  

Share Holding

Indian Promoters % 63.7 48.3 131.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 6.9 74.3%  
FIIs % 23.0 34.4 66.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 10.5 79.0%  
Shareholders   133,026 56,727 234.5%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   DR. DATSONS LABS  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare SUN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 178 Points Higher; Telecom and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest throughout the day today and ended on a positive note.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jul 3, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - AJANTA PHARMA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS